Drugs / BX005-A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05240300 | May 2022 → Jun 2023 | atopic eczema | BiomX, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BX005-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05240300 ↗ |
| Modality | Other / unclassified | “phage gel” NCT05240300 ↗ |
| Route | Topical | “administered topically” NCT05240300 ↗ |